Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients

Table 3 Studies comparing conventional and drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma patients

Ref.	Arm	Drug	Sample size	Study design	Region
1Nicolini et al[38]	DEB-TACE	Doxorubicin	22	R	Italy
	cTACE	Epirubicin	16
1Frenette et al[39]	DEB-TACE	Doxorubicin	35	R	United States
	cTACE	Doxorubicin	76
Song et al[40]	DEB-TACE	Doxorubicin	60	R	South Korea
	cTACE	Doxorubicin or Epirubicin/Cisplatin	69
Sacco et al[41]	DEB-TACE	Doxorubicin	33	RCT	Italy
	cTACE	Doxorubicin	34
van Malenstein et al[42]	DEB-TACE	Doxorubicin	16	RCT	Belgium
	cTACE	Doxorubicin	14
Lammer et al[43]	DEB-TACE	Doxorubicin	93	RCT	Europe
	cTACE	Doxorubicin	108
Golfieri et al[44]	DEB-TACE	Doxorubicin	89	RCT	Italy
	cTACE	Epirubicin	88
Ferrer Puchol et al[45]	DEB-TACE	Doxorubicin	47	P	Spain
	cTACE	Doxorubicin	25
Dhanasekaran et al[46]	DEB-TACE	Doxorubicin	45	R	United States
	cTACE	Doxorubicin/Cisplatin/Mytomicin-C	26
Wiggermann et al[47]	DEB-TACE	Epirubicin	22	R	Germany
	cTACE	Cisplatin	22
Recchia et al[48]	DEB-TACE	Doxorubicin	35	P	Italy
	cTACE	Doxorubicin	70
Megìas Vericat et al[49]	DEB-TACE	Doxorubicin	30	R	Spain
	cTACE	DOxorubicin	30

¹Study conducted on transplanted patients. DEB-TACE: Drug-eluting beads transarterial chemoembolization; cTACE: Conventional transarterial chemoembolization; R: Retrospective; RCT: Randomizes controlled trial; P: Prospective.